EconomyMarkets

CDC advisory panel in favor of Pfizer vaccine booster for ages 12 to 15 By Reuters

© Reuters. FILE PHOTO: Vials of the Pfizer-BioNTech coronavirus disease (COVID-19) pediatric vaccine are pictured in Lansdale, Pennsylvania, U.S., December 5, 2021. REUTERS/Hannah Beier

By Michael Erman

(Reuters) – A panel of outside experts advising the U.S. Centers for Disease Control and Prevention (CDC) on Wednesday voted to recommend booster shots of Pfizer Inc (NYSE:) and BioNTech SE (NASDAQ:)’s COVID-19 vaccine be made available to 12- to 15-year-olds.

The CDC’s Advisory Committee on Immunization Practices (ACIP) voted 13 to 1 to recommend that the U.S. health agency support booster shots for those aged 12 to 15 at least five months after their second dose.

The panel also said the CDC should strengthen its recommendation for boosters ages 16 and 17. The agency had previously made the shots available to those teenagers, but had stopped short of suggesting that all of them should receive the additional jab.

COVID-19 cases in the United States have hit record levels in recent days due to the fast spreading Omicron variant of the virus. Infection rates are surging as many workers and school children return from holiday vacations, raising the prospect of overwhelmed health systems as well as closed businesses and schools.

“COVID is overwhelming our hospitals and our children’s hospitals,” said panel member Dr. Katherine Poehling, a professor at Wake Forest School of Medicine. “This is a tool we need to use, and help our children through this pandemic.”

Data from Israel’s Health Ministry presented at the meeting suggested that vaccinated children aged 12 to 15 who were five to six months past their second dose were being infected at the same rate as unvaccinated kids by the Omicron variant of the virus. After receiving a booster shot, the infection rate dropped sharply, according to the data.

Dr. Peter Marks, a top regulator at the U.S. Food and Drug Administration, said that it is reasonable to extend the boosters down to 12- to 15-year-olds given the current surge in cases.

The FDA authorized the additional doses U.S. FDA authorizes Pfizer’s COVID-19 booster for 12- to 15-year-olds for the age group on Monday, but the CDC needs to sign off before the shots can be administered. CDC Director Rochelle Walensky is expected to weigh in quickly, allowing the boosters to begin as soon as this week.

Some scientists have expressed concerns about the booster shots due to rare cases of heart inflammation called myocarditis that have been linked to both the Pfizer/BioNTech and Moderna (NASDAQ:) vaccines, particularly in young men.

While there is limited data on myocarditis after booster doses for ages 12 to 15, the FDA has said evidence from both the United States and Israel indicates that the risk of myocarditis in men aged 18-40 is significantly lower after booster shots than after the second vaccine dose.

Only two cases of myocarditis were reported in Israel among 44,000 adolescents aged 12 to 15 who received a third dose of the Pfizer/BioNTech vaccine, the Israeli Health Ministry said on Wednesday.

Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.


Source link

Show More

Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *

Back to top button